Cargando…

Use of micro-positron emission tomography with (18)F-fallypride to measure the levels of dopamine receptor-D2 and (18)F-FDG as molecular imaging tracer in the pituitary glands and prolactinomas of Fischer-344 rats

Dopamine receptor-D2 (DRD2) is the most important drug target in prolactinoma. The aim of this current study was to investigate the role of using micro-positron emission tomography (micro-PET) with (18)F-fallypride and (18)F-fluorodeoxyglucose ((18)F-FDG) as molecular imaging tracer in the pituitary...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ping, Gui, Songbai, Cao, Lei, Gao, Hua, Bai, Jiwei, Li, Chuzhong, Zhang, Yazhuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827909/
https://www.ncbi.nlm.nih.gov/pubmed/27103832
http://dx.doi.org/10.2147/OTT.S94057
_version_ 1782426534045286400
author Li, Ping
Gui, Songbai
Cao, Lei
Gao, Hua
Bai, Jiwei
Li, Chuzhong
Zhang, Yazhuo
author_facet Li, Ping
Gui, Songbai
Cao, Lei
Gao, Hua
Bai, Jiwei
Li, Chuzhong
Zhang, Yazhuo
author_sort Li, Ping
collection PubMed
description Dopamine receptor-D2 (DRD2) is the most important drug target in prolactinoma. The aim of this current study was to investigate the role of using micro-positron emission tomography (micro-PET) with (18)F-fallypride and (18)F-fluorodeoxyglucose ((18)F-FDG) as molecular imaging tracer in the pituitary glands and prolactinomas of Fischer-344 (F344) rats and detect the difference of the levels of DRD2 in the pituitary glands and prolactinomas of F344 rat prolactinoma models. Female F344 rat prolactinoma models were established by subcutaneous administration of 15 mg 17β-estradiol for 8 weeks. The growth of tumors was monitored by the small-animal magnetic resonance imaging and micro-PET. A series of molecular biological experiments were also performed 4 and 6 weeks after pump implantation. The micro-PET molecular imaging with (18)F-fallypride revealed a decreased expression of DRD2 in F344 rat prolactinoma models, but the micro-PET molecular imaging with (18)F-FDG presented an increased uptake in the prolactinoma compared with the pituitary gland. A decreasing trend of levels of DRD2 in F344 rat prolactinoma models was also detected by molecular biological experiments. From this, we can conclude that micro-PET with (18)F-fallypride and (18)F-FDG can be used to assess tumorigenesis of the prolactinomas in vivo and molecular imaging detection of DRD2 level in prolactinoma may be an indication of treatment effect in the animal experiment.
format Online
Article
Text
id pubmed-4827909
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-48279092016-04-21 Use of micro-positron emission tomography with (18)F-fallypride to measure the levels of dopamine receptor-D2 and (18)F-FDG as molecular imaging tracer in the pituitary glands and prolactinomas of Fischer-344 rats Li, Ping Gui, Songbai Cao, Lei Gao, Hua Bai, Jiwei Li, Chuzhong Zhang, Yazhuo Onco Targets Ther Original Research Dopamine receptor-D2 (DRD2) is the most important drug target in prolactinoma. The aim of this current study was to investigate the role of using micro-positron emission tomography (micro-PET) with (18)F-fallypride and (18)F-fluorodeoxyglucose ((18)F-FDG) as molecular imaging tracer in the pituitary glands and prolactinomas of Fischer-344 (F344) rats and detect the difference of the levels of DRD2 in the pituitary glands and prolactinomas of F344 rat prolactinoma models. Female F344 rat prolactinoma models were established by subcutaneous administration of 15 mg 17β-estradiol for 8 weeks. The growth of tumors was monitored by the small-animal magnetic resonance imaging and micro-PET. A series of molecular biological experiments were also performed 4 and 6 weeks after pump implantation. The micro-PET molecular imaging with (18)F-fallypride revealed a decreased expression of DRD2 in F344 rat prolactinoma models, but the micro-PET molecular imaging with (18)F-FDG presented an increased uptake in the prolactinoma compared with the pituitary gland. A decreasing trend of levels of DRD2 in F344 rat prolactinoma models was also detected by molecular biological experiments. From this, we can conclude that micro-PET with (18)F-fallypride and (18)F-FDG can be used to assess tumorigenesis of the prolactinomas in vivo and molecular imaging detection of DRD2 level in prolactinoma may be an indication of treatment effect in the animal experiment. Dove Medical Press 2016-04-06 /pmc/articles/PMC4827909/ /pubmed/27103832 http://dx.doi.org/10.2147/OTT.S94057 Text en © 2016 Li et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Li, Ping
Gui, Songbai
Cao, Lei
Gao, Hua
Bai, Jiwei
Li, Chuzhong
Zhang, Yazhuo
Use of micro-positron emission tomography with (18)F-fallypride to measure the levels of dopamine receptor-D2 and (18)F-FDG as molecular imaging tracer in the pituitary glands and prolactinomas of Fischer-344 rats
title Use of micro-positron emission tomography with (18)F-fallypride to measure the levels of dopamine receptor-D2 and (18)F-FDG as molecular imaging tracer in the pituitary glands and prolactinomas of Fischer-344 rats
title_full Use of micro-positron emission tomography with (18)F-fallypride to measure the levels of dopamine receptor-D2 and (18)F-FDG as molecular imaging tracer in the pituitary glands and prolactinomas of Fischer-344 rats
title_fullStr Use of micro-positron emission tomography with (18)F-fallypride to measure the levels of dopamine receptor-D2 and (18)F-FDG as molecular imaging tracer in the pituitary glands and prolactinomas of Fischer-344 rats
title_full_unstemmed Use of micro-positron emission tomography with (18)F-fallypride to measure the levels of dopamine receptor-D2 and (18)F-FDG as molecular imaging tracer in the pituitary glands and prolactinomas of Fischer-344 rats
title_short Use of micro-positron emission tomography with (18)F-fallypride to measure the levels of dopamine receptor-D2 and (18)F-FDG as molecular imaging tracer in the pituitary glands and prolactinomas of Fischer-344 rats
title_sort use of micro-positron emission tomography with (18)f-fallypride to measure the levels of dopamine receptor-d2 and (18)f-fdg as molecular imaging tracer in the pituitary glands and prolactinomas of fischer-344 rats
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827909/
https://www.ncbi.nlm.nih.gov/pubmed/27103832
http://dx.doi.org/10.2147/OTT.S94057
work_keys_str_mv AT liping useofmicropositronemissiontomographywith18ffallypridetomeasurethelevelsofdopaminereceptord2and18ffdgasmolecularimagingtracerinthepituitaryglandsandprolactinomasoffischer344rats
AT guisongbai useofmicropositronemissiontomographywith18ffallypridetomeasurethelevelsofdopaminereceptord2and18ffdgasmolecularimagingtracerinthepituitaryglandsandprolactinomasoffischer344rats
AT caolei useofmicropositronemissiontomographywith18ffallypridetomeasurethelevelsofdopaminereceptord2and18ffdgasmolecularimagingtracerinthepituitaryglandsandprolactinomasoffischer344rats
AT gaohua useofmicropositronemissiontomographywith18ffallypridetomeasurethelevelsofdopaminereceptord2and18ffdgasmolecularimagingtracerinthepituitaryglandsandprolactinomasoffischer344rats
AT baijiwei useofmicropositronemissiontomographywith18ffallypridetomeasurethelevelsofdopaminereceptord2and18ffdgasmolecularimagingtracerinthepituitaryglandsandprolactinomasoffischer344rats
AT lichuzhong useofmicropositronemissiontomographywith18ffallypridetomeasurethelevelsofdopaminereceptord2and18ffdgasmolecularimagingtracerinthepituitaryglandsandprolactinomasoffischer344rats
AT zhangyazhuo useofmicropositronemissiontomographywith18ffallypridetomeasurethelevelsofdopaminereceptord2and18ffdgasmolecularimagingtracerinthepituitaryglandsandprolactinomasoffischer344rats